Compare ARLP & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARLP | BLLN |
|---|---|---|
| Founded | 1971 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | Coal Mining | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | 1999 | N/A |
| Metric | ARLP | BLLN |
|---|---|---|
| Price | $25.78 | $79.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $29.50 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 340.8K | 302.3K |
| Earning Date | 04-27-2026 | 03-04-2026 |
| Dividend Yield | ★ 9.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $2,002,857,000.00 | N/A |
| Revenue This Year | $2.20 | $45.96 |
| Revenue Next Year | $3.57 | $30.11 |
| P/E Ratio | $10.68 | ★ N/A |
| Revenue Growth | ★ 11.50 | N/A |
| 52 Week Low | $22.53 | $61.96 |
| 52 Week High | $29.45 | $138.70 |
| Indicator | ARLP | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 36.05 | 51.79 |
| Support Level | $24.68 | $80.39 |
| Resistance Level | $25.87 | $83.20 |
| Average True Range (ATR) | 0.78 | 7.16 |
| MACD | -0.35 | 0.45 |
| Stochastic Oscillator | 10.99 | 50.69 |
Alliance Resource Partners LP operates as a coal mining company based in the United States. It has four segments: Illinois Basin, Appalachia, Oil & Gas Royalties, and Coal Royalties. The Illinois Basin comprises underground mining complexes in Illinois, Indiana, Kentucky, Maryland, and West Virginia. The Appalachia segment comprises the Mettiki mining complex, the Tunnel Ridge mining complex, and the MC Mining complex. The Oil & Gas Royalties has oil & gas mineral interests held by AR Midland and AllDale I & II, and includes Alliance Minerals' equity interests in both AllDale III and Cavalier Minerals. The Coal Royalties have included coal mineral reserves and resources owned or leased by Alliance Resource Properties.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.